Almost everyone considering fertility treatment has heard of IVF. Substantially fewer have heard of in vitro maturation, or IVM, despite its being an established option in specific clinical situations.
The distinction lies in where the egg matures. Conventional IVF uses one to two weeks of gonadotropin injections to drive multiple follicles to maturity inside the ovary before retrieval. IVM retrieves the eggs while they are still immature and completes maturation in the laboratory over 24 to 48 hours.
The practical consequences are a shorter cycle, a substantially reduced hormone load, and a lower risk of ovarian hyperstimulation syndrome. For women with polycystic ovary syndrome, who carry the highest OHSS risk of any group undergoing stimulation, that risk profile is the central consideration. IVM does not suit every patient, and reported per-cycle live birth rates remain lower than conventional IVF, so candidate selection matters.
What is IVM (In Vitro Maturation)
IVM is a fertility treatment in which immature eggs are collected from small follicles in the ovary and cultured in a specially formulated medium for approximately 24 to 48 hours until they reach maturity. The mature eggs are then fertilized with sperm, usually through intracytoplasmic sperm injection (ICSI), and the resulting embryos are cultured and transferred to the uterus.
The difference between the two techniques lies in a single step. In IVF, the ovaries carry out maturation under the influence of daily hormone injections. In IVM, the laboratory carries out maturation, which means the injections are reduced to a minimum or omitted altogether.
IVM is not an experimental procedure. The American Society for Reproductive Medicine stated in its 2021 committee opinion that the technique should no longer be described as experimental when performed in centers with appropriate laboratory capability. That qualification is significant, and it explains why IVM remains available in a limited number of clinics compared with IVF.
How In Vitro Maturation Treatment Works
An in vitro maturation treatment cycle is shorter and involves a lower drug burden than an IVF cycle, though the laboratory work behind it is more demanding.
- Baseline assessment: An ultrasound scan counts the antral follicles and blood tests measure anti-Müllerian hormone (AMH) and other hormone levels. A high antral follicle count, which increases risk in IVF, is an advantage in IVM.
- Minimal or no ovarian stimulation: Some protocols use a short course of low-dose follicle-stimulating hormone (FSH) over approximately three days, or a trigger injection shortly before retrieval. Other protocols use no stimulation at all. In either case, the medication load is a fraction of that used in a conventional IVF cycle.
- Egg retrieval: Immature eggs are collected from small follicles under sedation using a finer needle than the one used in conventional retrieval. The experience for the patient is comparable to an IVF retrieval.
- Laboratory maturation: The retrieved eggs are placed in a culture medium containing the hormones and growth factors they would ordinarily receive within the follicle. Over the following 24 to 48 hours, the embryology team assesses which eggs have reached the mature stage.
- Fertilization: Mature eggs are fertilized, most commonly by ICSI. Eggs matured in the laboratory develop a modified outer layer that makes conventional fertilization less reliable, which is why direct sperm injection is preferred.
- Embryo culture and transfer: Embryos are cultured over the subsequent days. Depending on the protocol and the condition of the uterine lining, the transfer may be performed in the same cycle, or the embryos may be frozen for transfer at a later date.
Newer biphasic protocols, described as capacitation IVM, introduce a pre-maturation culture stage before final maturation. The intention is to improve the proportion of eggs that mature well enough to produce usable embryos.
Why IVM Is Considered a Low Hormone IVF Alternative
The description of IVM as a low hormone IVF alternative reflects the patient’s experience of treatment rather than the complexity of the laboratory process.
- Reduced injection burden: A conventional IVF cycle typically involves daily gonadotropin injections over 8 to 12 days. IVM protocols use a fraction of that, and certain protocols use none.
- Lower medication cost: Stimulation drugs represent one of the largest components of the cost of an IVF cycle, so reducing them reduces the overall expense.
- Reduced monitoring requirement: A lower level of stimulation means a smaller number of scans and blood tests, which is relevant for working women and for patients traveling from other cities.
- Very low risk of OHSS: Because the ovaries are not driven to produce a large cohort of mature follicles, the complication the technique was designed to avoid rarely arises.
- Lower estrogen exposure: Estrogen levels remain close to physiological, which is clinically relevant for women with hormone-sensitive conditions.
A lower medication load does not automatically translate into a better clinical outcome, which the following comparison addresses.
IVM vs IVF
| IVM | IVF | |
| Hormone injections | Minimal or none | Daily for approximately 8 to 12 days |
| Eggs at retrieval | Immature | Mature |
| Site of maturation | Laboratory culture | Within the ovary |
| Risk of OHSS | Very low | Present, higher in PCOS and high AMH |
| Usual fertilization method | ICSI | Conventional IVF or ICSI |
| Medication cost | Lower | Higher |
| Monitoring visits | Reduced | More frequent |
| Availability | Limited to specialized laboratories | Widely available |
| Evidence base | Growing, smaller body of data | Extensive, accumulated over decades |
The trade-off in IVM vs IVF is straightforward. IVM reduces drug exposure, cost, and complication risk. Conventional IVF, in most patient groups studied to date, continues to produce a higher probability of live birth per cycle started, because not every immature egg matures successfully in culture and not every matured egg fertilizes normally.
For certain patients, that trade-off is clinically appropriate. For others it is not. The decision depends on factors such as the underlying diagnosis, ovarian reserve, and previous response to stimulation rather than on a preference for a reduced number of injections.
IVM Fertility Treatment for PCOS
PCOS is the setting in which IVM fertility treatment for PCOS has the strongest clinical rationale, for three reasons.
First, polycystic ovaries contain a large number of small antral follicles, and small follicles are precisely what the technique harvests. The feature that makes ovarian stimulation risky is the same feature that makes IVM workable.
Second, women with PCOS carry the highest risk of OHSS during conventional IVF. Severe OHSS can involve fluid accumulation in the abdomen, an increased risk of clotting, and hospital admission. Avoiding the complication altogether rather than managing it after it develops represents a meaningful clinical benefit.
Third, women with PCOS often respond unpredictably to gonadotropins. Certain cycles are canceled for over-response, while others require a freeze-all approach with the transfer deferred.
IVM removes a substantial part of that uncertainty from the beginning of the cycle.
Research shows that in women with PCOS, IVM is associated with a markedly reduced risk of ovarian hyperstimulation syndrome (OHSS), with several studies reporting no cases of OHSS in the IVM group. However, live birth rates have generally been lower with IVM than with conventional IVF in the cycles studied.
Who Is Eligible for IVM
Eligibility is determined on a case-by-case basis. The groups most commonly considered include:
- Women with PCOS or polycystic ovarian morphology, particularly those with a high antral follicle count and elevated AMH, are considered ideal candidates for IVM.
- Women who have previously developed OHSS during a stimulated cycle, or whose cycle was canceled because of over-response.
- Patients requiring urgent fertility preservation before cancer treatment. IVM can be initiated at short notice without waiting for a particular point in the menstrual cycle, which is relevant when chemotherapy is scheduled within days.
- Women with hormone-sensitive cancers, including certain breast cancers, where the treating team wishes to avoid raising estrogen levels.
- Women who are unable to take gonadotropins for medical reasons, or who have experienced severe reactions to stimulation medication.
- Selected cases of resistant ovary syndrome, in which follicles are present but do not respond to normal hormonal signals.
IVM is generally not the preferred option for women with diminished ovarian reserve and a low antral follicle count, since the technique depends on retrieving a reasonable number of immature eggs. Age remains a determining factor, as it does across all fertility treatments, because egg quality declines irrespective of where maturation takes place.
Conclusion
IVM offers a genuine alternative for a defined group of patients, most notably women with PCOS, women with a history of OHSS, and those requiring rapid fertility preservation. It reduces medication exposure, cost, and the risk of a serious complication.
What it does not offer is a universal replacement for IVF. The evidence to date indicates lower live birth rates per cycle in most populations studied, and the technique depends on laboratory expertise that is not uniformly available. The appropriate question is not which treatment is superior in general terms, but which is better suited to an individual clinical picture.
Speak to a Fertility Specialist at 9M Fertility
Selecting between IVM and IVF is a clinical decision that requires individual assessment. The specialists at 9M Fertility evaluate both partners, review ovarian reserve and previous treatment response, and explain the reasoning behind the recommended protocol along with realistic expectations for each option.
Book a consultation with 9M Fertility to determine which fertility treatment suits your diagnosis. Contact Us
